Inappropriate TLR9 activation has been reported in malignant B-cells [38] and we observed a decreased risk of B-NHL (OR = 0.67) and DLBCL (OR = 0.66) for carriers of the TLR9 (rs5743836) C allele. Here, TLR9 is linked to diffuse large B-cell lymphoma.